BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,335.40
- Market cap
- ₹1,11,463 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 39.8×Sector 46.1×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Dr. Reddy's Laboratories Other Announcement
Dr. Reddy's Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, including notes on significant beneficial ownership.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's received DCGI approval for Zytorvi in advanced esophageal cancer, its second Indian indication. This expands first-line immunotherapy access in its oncology portfolio.
Other management change announcements
All →Hexaware Technologies Management Change
Hexaware appointed Arjun Shah and Gregory Zeluck as Non-Executive Directors from 28 October 2026. Directors Neeraj Bharadwaj and Julius Genachowski resigned, and Girish Pai's resignation is effective 13 November 2026.
GMR Airports Management Change
GMR Airports appointed Sanjeev Gupta as Executive Director (Deputy CEO) effective 29 October 2026. Non-Executive Director Alexis Riols resigned effective 28 October 2026.
Raymond Realty Management Change
Raymond Realty said joint statutory auditor Chaturvedi & Shah LLP resigned on 28 October 2026 after a dispute over audit fee revision. Walker Chandiok & Co LLP continues as the other statutory auditor.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.
TruCap Finance Management Change
TruCap Finance designated three employees as Senior Management Personnel, effective 29 October 2026. The changes are additional charges for Product, Operations and Contact Centre roles.
Sayaji Hotels (Indore) Management Change
Sayaji Hotels (Indore) appointed Azhar Yusuf Dhanani as Additional Non-Executive Non-Independent Director effective October 28, 2026. Shareholder approval is required within three months.